Halozyme Therapeutics | HALO - 流动资产



金融业
股票价格
USD
资产
USD 2.53B
现金及等价物
USD 133.82M
销售成本
USD 102.15M
流动资产
USD 825.21M
流动负债
USD 177.09M
债务
USD 1.51B
EBIT
USD -88.41M
EBITDA
USD 21.9M
员工
350
EPS每股收益
USD -0.24
股本和储备
USD 48.81M
销售毛利
USD 281.77M
债务利息支出
USD 4.91M
贷款资金
USD 2.14B
市值
USD 8.19B
净收入
USD -141.59M
营业费用
USD 211.07M
营业利润
USD -88.41M
普通股股本
USD 117.78M
PE价格收益
23.16
税前利润
USD 218.96M
销售收入
USD 451.76M
销售和管理费用
USD 64.64M
股票
USD 176.48M
贸易债权人
USD 20.9M
应收帐款人
USD 441.27M


流动资产 更改 日
Acadia Pharmaceuticals USD 1.06B 14.31M 2025-12
Agios Pharmaceuticals USD 834.84M 107.21M 2026-03
Alnylam Pharmaceuticals USD 4.05B 97.85M 2025-12
Amarin USD 626.02M 23.87M 2026-03
Amgen USD 29.06B 1.17B 2025-12
Baxter International USD 6.87B 61M 2025-12
Cara Therapeutics USD 38.44M 4.69M 2025-09
Cytokinetics USD 916.97M 60.37M 2025-12
DBV Technologies USD 88.88M 32.36M 2025-09
Eli Lilly USD 55.63B 6.44B 2025-12
Esperion Therapeutics USD 462.57M 102.11M 2025-12
Halozyme Therapeutics USD 825.21M 503.54M 2025-12
Intrexon USD 23.72M 45.04M 2024-06
Ionis Pharmaceuticals USD 2.99B 471.01M 2025-12
MannKind USD 291.58M 67.26M 2025-12
Minerva Neurosciences USD 83.1M 70.08M 2025-12
Nektar Therapeutics USD 266.27M 15.09M 2025-12
Pfizer USD 46.92B 3.22B 2025-09
Rigel Pharmaceuticals USD 214.93M 39.53M 2025-09
United Therapeutics USD 3.7B 208.5M 2025-12
Vanda Pharmaceuticals USD 347.26M 20.23M 2025-12